Grant: Doctoral: Vanier Canada Graduate Scholarships
Université Laval
$150,000.00
Therapy development for pediatric diseases by gene correction in vivo
EF 2016-17
Résumé
Type 1 hereditary tyrosinemia (HT1 is caused by lack of the enzyme fumarylacetoacetase (FAH) needed to metabolize tyrosine present in the protein intake of our food. By-products of this amino acid build up, lead to a variety of symptoms including liver and kidney dysfunctions, cancers and death. Birth incidence of HT1 is 1/100,000 worldwide but startling in some regions of Quebec where it affects over 1/1,846 individuals. For genetic diseases that manifest at a young age with irreversible consequences, such as HT1, early treatment is critical and essential. Neonatal gene therapy using viral vectors has the potential advantage of achieving therapeutic effects before disease manifestation and the vector faces a relatively immature immune system. However, treatment of infants faces a major challenge because the loss of episomal vector genomes during liver growth results in the rapid extinction of therapeutic genes expression. In this work, We are going to use a CRISPR/Cas9 based genome editing to induce the integration of a therapeutic FAH gene in a genomic self harbour situated in the albumin gene locus. Experiments will be done in vivo using a mouse model having a lack of the FAH enzyme. Our goal is to translate an innovative genome editing technology into a novel class of human therapeutics that enables precise molecular modification of a genetic defect. Our long-term objective is to develop gene therapies using genome-editing technologies to treat rare inherited metabolic diseases affecting children, such as HT1. We are also interested to improve our knowledge on mechanisms of gene repair. Importantly, this strategy represents a generic approach. HT1 is a well-described model of liver disease; hence we suggest that our approach could be translated to other metabolic diseases for which no treatment exists. Ultimately, this research proposal may lead to significant improvements in quality of life for children and their families affected by rare diseases.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
362458
Name
Agudelo Daniel S
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Therapy development for pediatric diseases by gene correction in vivo
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Viral Vectors; Crispr/Cas9; Genome Editing; Pediatric Diseases
Abstract
Type 1 hereditary tyrosinemia (HT1 is caused by lack of the enzyme fumarylacetoacetase (FAH) needed to metabolize tyrosine present in the protein intake of our food. By-products of this amino acid build up, lead to a variety of symptoms including liver and kidney dysfunctions, cancers and death. Birth incidence of HT1 is 1/100,000 worldwide but startling in some regions of Quebec where it affects over 1/1,846 individuals. For genetic diseases that manifest at a young age with irreversible consequences, such as HT1, early treatment is critical and essential. Neonatal gene therapy using viral vectors has the potential advantage of achieving therapeutic effects before disease manifestation and the vector faces a relatively immature immune system. However, treatment of infants faces a major challenge because the loss of episomal vector genomes during liver growth results in the rapid extinction of therapeutic genes expression. In this work, We are going to use a CRISPR/Cas9 based genome editing to induce the integration of a therapeutic FAH gene in a genomic self harbour situated in the albumin gene locus. Experiments will be done in vivo using a mouse model having a lack of the FAH enzyme. Our goal is to translate an innovative genome editing technology into a novel class of human therapeutics that enables precise molecular modification of a genetic defect. Our long-term objective is to develop gene therapies using genome-editing technologies to treat rare inherited metabolic diseases affecting children, such as HT1. We are also interested to improve our knowledge on mechanisms of gene repair. Importantly, this strategy represents a generic approach. HT1 is a well-described model of liver disease; hence we suggest that our approach could be translated to other metabolic diseases for which no treatment exists. Ultimately, this research proposal may lead to significant improvements in quality of life for children and their families affected by rare diseases.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Agudelo, Daniel S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~